Ibuprofen is a nonsteroidal anti-inflammatory and antirheumatic drug that can be used to relieve mild to moderate pain and high fever
caused by colds.
Recently, with the continuous optimization of epidemic prevention and control policies, ibuprofen has shown a situation
of "one (bottle) is difficult to find".
According to data forecasts, the sales of ibuprofen in 2022 are expected to exceed 1.
4 billion yuan, and from the perspective of drug treatment, internal products account for more than 98%.
Among them, Johnson & Johnson's ibuprofen suspension and Sino-American Tianjin SmithKline Pharmaceutical's ibuprofen sustained-release capsules have been seizing the market highland, and sales are expected to exceed 400 million yuan
in 2022.
The industry pointed out that the market scale of anti-inflammatory and anti-rheumatic drugs in retail pharmacies continued to rise, attracting more and more companies to rush into the market
.
According to data, since the beginning of this year, 14 new anti-inflammatory and anti-rheumatic drugs (by product + enterprise statistics) have been approved for marketing
.
Among them, ibuprofen is currently a hot variety in the anti-inflammatory and anti-rheumatic drug market, and ibuprofen suspension, ibuprofen softgels and arginine ibuprofen granules will welcome new enterprises in 2022
.
Among them, the companies that will be approved for marketing in 2022 include Hubei Duorui Pharmaceutical and China Resources Sanjiu; The company that was approved for listing in ibuprofen softgels in 2022 is Fupuke Pharmaceutical (Wuhan); The companies that will be approved for listing of arginine ibuprofen granules in 2022 include Anhui Huachen Pharmaceutical and Jiangxi Western European Pharmaceutical
.
It is reported that CR Sanjiu has been approved for ibuprofen tablets, arginine ibuprofen powder, arginine ibuprofen granules earlier, and won the ibuprofen suspension this year, and the company's ibuprofen product matrix has added another heavy member
.
CR Sanjiu said on the investor interactive platform on December 14 that CR Sanjiu "ibuprofen suspension" has been approved for marketing by the National Medical Products Administration, further enriching the company's pediatric product line, and the company is accelerating the product listing process
.
Renfu Pharmaceutical has already obtained the production approval of ibuprofen tablets and ibuprofen suspension, and this year added ibuprofen softgels
.
Renfu Pharmaceutical's subsidiaries produce and sell ibuprofen tablets, ibuprofen softgels and ibuprofen suspensions in China, and ibuprofen tablets and ibuprofen softgels
in the US market.
It is reported that on December 15, the Hubei Provincial Food and Drug Administration issued an emergency production license for the domestic production line of Fupuke ibuprofen capsules, and the relevant production lines have rapidly increased from the original 4 to 8, and the daily production capacity has now increased to 1 million capsules, and it is expected to double the production capacity by the end of December to 2 million capsules per day, and pass the "mark"
of 6 million capsules per day in the middle of 2023.
It is reported that in the future, the whole country will usher in the peak of the epidemic, ibuprofen is expected to be hot for a while, if the production enterprises can seize the opportunity, while doing a good job in supply, it is also a good time to promote the brand, a new round of market reshuffle has begun
.
The data shows that China is the world's large-scale ibuprofen API production and export country, and the ibuprofen produced in China accounts for 1/3 of the global production capacity, of which the production capacity of Xinhua Pharmaceutical ibuprofen API is 8,000 tons, and the production capacity of Hengdi Pharmaceutical is 3,500 tons
.
It is reported that the two major manufacturers have expansion plans, and Xinhua Pharmaceutical recently said that it will expand production capacity to ensure market supply and ensure that the production capacity of key drugs such as ibuprofen will be doubled
by the end of December 2022.
Hendi Pharmaceutical said on the investor interactive platform that after the completion of the 5,000 tons of ibuprofen API project, it will reach an annual production capacity of 8,500 tons
.
={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"share:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
appendChild(createElement('script')).
src='http://bdimg.
share.
baidu.
com/static/api/js/share.
js?v=89860593.
js?cdnversion='+~(-new Date()/36e5)]; 
